Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SURF

Surface Oncology (SURF) Stock Price, News & Analysis

Surface Oncology logo

About Surface Oncology Stock (NASDAQ:SURF)

Advanced Chart

Key Stats

Today's Range
$1.07
$1.07
50-Day Range
$0.88
$1.08
52-Week Range
$0.56
$1.43
Volume
N/A
Average Volume
430,375 shs
Market Capitalization
$65.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

SURF Stock News Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Q3 2024 Heron Therapeutics Inc Earnings Call
See More Headlines

SURF Stock Analysis - Frequently Asked Questions

Surface Oncology, Inc. (NASDAQ:SURF) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04. The firm had revenue of $0.39 million for the quarter.

Surface Oncology (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Surface Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD), NIO (NIO), Zoom Video Communications (ZM), QUALCOMM (QCOM) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
11/04/2021
Today
5/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SURF
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,590,000.00
Pretax Margin
-211.95%

Debt

Sales & Book Value

Annual Sales
$30 million
Price / Cash Flow
N/A
Book Value
$0.81 per share
Price / Book
1.32

Miscellaneous

Free Float
53,525,000
Market Cap
$65.08 million
Optionable
Not Optionable
Beta
1.75
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SURF) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners